Clinical trial failures

Sponsor hub

National Institute of Allergy and Infectious Diseases (NIAID) clinical trial failures

Review 179 stopped clinical trials from National Institute of Allergy and Infectious Diseases (NIAID), including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 20 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials179
Likely biological signals20
Shown below100

Dominant stop reasons

OTHER/UNKNOWN
100
OPERATIONAL
58
EFFICACY/FUTILITY
11
SAFETY
9
REGULATORY
1

Notable sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
179

Related phases

Phase I
72
Phase II
65
Unknown
16
Phase IV
11
Phase III
10

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT07208760: L9LS-R21 Interaction

Phase II Malaria trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OTHER/UNKNOWN.

After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol.

NCT05574335: Siplizumab in T1DM

Phase I Type 1 Diabetes Mellitus trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OPERATIONAL.

Prior to termination the DESIGNATE study was an on enrollment hold due to greater than anticipated lymphodepletion. The pharmaceutical partner decided not to reopen its own T1D trial and ceased development of siplizumab in autoimmunity.

NCT02422524: Pretomanid in Adults With Hepatic Impairment

Phase I Tuberculosis trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OPERATIONAL.

The TB hepatic pretomanid PK trial is closed to enrollment. There is no possibility of enrolling and completing the CSR before November 2024.

NCT03916185: Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Phase I Respiratory Syncytial Virus (RSV) trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OPERATIONAL.

The study closed to enrollment prior to fully accruing due to difficulties with slower than expected accrual.

NCT03654040: Liver Transplantation With Tregs at UCSF

Phase I Liver Transplant trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OTHER/UNKNOWN.

The study was terminated by the Sponsor prior to any participants receiving the investigational product.

NCT03705169: Pharmacokinetics and Safety of SAR441236

Phase I HIV-1-infection trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OPERATIONAL.

The study closed to enrollment and follow-up in May 2023. There had been no enrollment since October 2021, and by 2023, the available study product had reached its expiration date. Enrollment targets in Arm B had not been met.

NCT00863057: Combination Pain Therapy in HIV Neuropathy

Phase II HIV Infections trial by National Institute of Allergy and Infectious Diseases (NIAID). Stop reason: OPERATIONAL.

Due to slow rate of enrollment, which compromised the ability to meet study objectives in a timely manner.